PEDIATRICS Vol. 53 No. 3 March 1974, pp. 445
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pilch, B. Z.
Right arrow Articles by Kahn, C. R.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Pilch, B. Z.
Right arrow Articles by Kahn, C. R.

Letter to the Editor

Ben Z. Pilch M.D.1 and C. Ronald Kahn M.D.2

1 Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts 02114
2 Clinical Endocrinology Branch, National Institute of Arthritis, Metabolism, and Digestive Diseases, National Institutes of Health Bethesda, Maryland 20014

We appreciate Dr. Mosier's thoughtful comments and agree that it is indeed unfortunate that the information as to the precise dosage of I131 administered to the patient under discussion is not available. We do feel, however, that a dosage estimate of 25µc is not unreasonable. A study from the Michael Reese Hospital appearing in January 1957 reported using I131 tracer doses of 22 to 25µc in children under 10 years of age (one as young as 23frac12 months) to determine thyroidal I131 uptakes and PBI131 levels.